GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...
GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...
Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...
The directive follows a post-marketing study by the regulator, which found that patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo are at greater risks ... Tuesday’s safety update is the ...
U.S. sales of RSV vaccines have declined after regulators narrowed the age group eligible for the shots and determined they would be a one-time vaccination for now. For Pfizer and GSK, RSV ...
A small number of participants in clinical trials developed serious neurologic conditions, including Guillain-Barré syndrome (GBS), after receiving GSK's Arexvy or Pfizer's Abrysvo. Available data ...
(Reuters) - GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug ...